The assessment of effect of sacubitril/valsartan combination in patients with heart failure and reduced ejection fraction: a single center study

Background: sacubitril/valsartan approved in 2015 to use in heart failure patients with reduced ejection fraction and dramatic results gained, the effects of it in heart failure patients is assessed by many clinical parameters. Aims: Assessment the role of sacubitril/valsartan combination as Angiotensin Receptor Neprilysin Inhibitor in heart failure patients in AL Nasiriyaha Heart Centre-Iraq by explain the dramatic effect of sacubitril/valsartan in improve the clinical state of patients. Patients and Methods: This is interventional study that included 73 patients with heart failure patients and reduced ejection fraction who visited the cardiac outpatient clinic in AL Nasiriyaha Heart Centre Thi-Qar Iraq who received Sacubitril/Valsartan as Angiotensin Receptor Neprilysin Inhibitor, study period was two months. Results: This study explained the role of sacubitril/valsartan combination in improve clinical states of patients by follow-up the sample from heart failure and reduced ejection fraction patients. Conclusions: Sacubitril and Valsartan demonstrated clinical efficacy in treatments of heart failure patients with reduced ejection fraction in the Nasiriyah Heart Center, Thi-Qar province, by improving vital signs related to disease.